Clinical Trials | November 15, 2023
Teva, Royalty Pharma collaborate to further accelerate Olanzapine LAI program
Phase 3 data expected in the second half of 2024
Phase 3 data expected in the second half of 2024
Yesafili, received marketing authorization approval from the European Commission for the European Union
The company has raised US$4.5 million in funding for its AI operating system
Digitally enabled drug discovery for oncology with potential to accelerate the delivery of new cancer therapies to patients
This collaboration underscores WOTR's unwavering commitment to strengthening rural communities against the unpredictable variations of climate change
Sales in the US region grew well, partially offset by the decline in the LATAM and European regions
he company posted total income during Q2 FY24 at Rs. 12.86 crore
European operations' revenue grew 58.4% to Rs 599.7 crore
General Medicine grows 5% and Vaccines 10% led by Shingrix
Q2FY24 EBITDA up by 105% y-o-y at Rs. 28 crore
Subscribe To Our Newsletter & Stay Updated
